Testing new imaging scans to better detect advanced bladder cancer

Plain-English translation of NCT07750470 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

What is this trial?

This trial is testing whether a specialized imaging scan called 18F-FDG PET/CT can better detect advanced bladder cancer and predict how well patients will respond to chemotherapy treatment. The study compares this new scan with standard imaging tests in patients who have been newly diagnosed with muscle-invasive bladder cancer and are eligible for chemotherapy.

Doctors need better tools to detect how far advanced bladder cancer has spread and to predict early on which patients will benefit most from chemotherapy. The new imaging approach being tested may help answer these questions more accurately than current standard scans.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been newly diagnosed with high-grade, muscle-invasive bladder cancer confirmed by biopsy
you are healthy enough to receive platinum-based chemotherapy (with good kidney function and no serious nerve damage or hearing loss)
you can tolerate the imaging procedures without claustrophobia or severe anxiety
you do not have an allergy to contrast dye used in CT scans, or your allergy can be managed

You likely don't qualify if…

you have a history of other cancers
you have non-muscle-invasive or low-grade bladder cancer
you have significant kidney disease (creatinine clearance below 60 mL/min)
you have severe nerve damage, hearing loss, or heart problems that would make chemotherapy unsafe
you have uncontrolled diabetes or severe claustrophobia that prevents imaging

What participation looks like

You will undergo specialized imaging scans at the start of your chemotherapy treatment and again after two cycles of chemotherapy. Each visit involves two types of scans—a PET/CT scan (which shows how active cancer cells are) and a standard CT scan (which shows detailed pictures of your organs). The study compares how well these scans work together to detect your cancer and predict your response to treatment. The entire study spans several weeks as you receive your standard chemotherapy.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

Trial locations(1 site)

Italy

Azienda Ospedaliero-Universitaria di Ferrara, Ferrara